Project Description

Insights Into the Market for Infliximab

Presented by Policy Reporter, a TrialCard company

ABSTRACT

Gain critical insights into the US biosimilar landscape to help drive your biosimilar strategy. Through a synthesis of proprietary and public data, we analyze the market for Infliximab (Remicade® and its biosimilar competitors) to discuss potential predictors of future market behavior.

Biosimilar manufacturers should be aware that they’ll need to go beyond pricing discounts and develop partnerships with friendly constituents to expand market share and ensure the continued viability of the market.

Please submit the form below to view this resource.

Request Resource